By Steven ScheerJERUSALEM (Reuters) - Teva Pharmaceutical Industries said it was set to launch its long awaited biosimilar ...

I write about healthcare policy, with an emphasis on Rx drugs. As of March, the blockbuster autoimmune drug Humira ...

AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group's CEO ...

Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to ...

AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S.

Adalimumab-aaty will be priced at an 85% discount to HUMIRA ® (adalimumab) Branded and unbranded versions of Celltrion USA's ...

Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average of ...

AbbVie warned Friday that sales of its blockbuster arthritis drug, Humira, will continue to lose market share to biosimilars.

In its opening months, after spinning off as a separate business from Novartis, Sandoz is riding the wave of a strong launch of its biosimilar version of AbbVie’s Humira (adalimumab). | After spinning ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Chris Shibutani ...

Share this link with them to sign up. Good morning! Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper biosimilars in the U.S. and abroad.